Search
lurasidone (Latuda)
Indications:
- treatment of schizophrenia in adults
- mania [2]
- psychosis & agitation in the elderly [3]
- biopolar depression*
* copius television advertisement for using Lutuda to treat bipolar depression
Dosage:
- 40-80 mg* PO [3]
* do not exceed 40 mg in patients concurrently taking CYP3A4 inhibitor [3]
Pharmacokinetics:
- metabolized by CYP3A4 [3]
Adverse effects:
- drowsiness, sedation
- agitation, tremors
- nausea
- no weight gain (per manufacturer)
- risk for death when used off-label to treat psychosis & agitation in the elderly
- black box warning [3]
- increased risk of hyperglycemia
- increased risk of cerebrovascular events
- increased risk of mortality in patients with dementia
Drug interactions:
- plasma levels increased by CYP3A4 inhibitors [3]
Laboratory:
- lurasidone in urine
Interactions
drug adverse effects of antipsychotic agents
monitor with atypical antipsychotic agents
General
atypical antipsychotic agent; second generation antipsychotic
heterocyclic compound, 1 ring
Database Correlations
PUBCHEM correlations
References
- Physician's First Watch for November 1, 2010
Massachusetts Medical Society
http://www.jwatch.org
- FDA NEWS RELEASE, Oct. 28, 2010
FDA approves Latuda to treat schizophrenia in adults
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm
- Deprecated Reference
- Geriatric Review Syllabus, 8th edition (GRS8)
Durso SC and Sullivan GN (eds)
American Geriatrics Society, 2013